株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Celsion Corporation - 製品パイプライン分析

Celsion Corporation - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 253760
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Celsion Corporation - 製品パイプライン分析 Celsion Corporation - Product Pipeline Review - 2015
出版日: 2015年05月29日 ページ情報: 英文 49 Pages
概要

Celsion Corporationは米国に本社を置くバイオ製薬企業で、革新的な癌治療薬の開発と商品化に注力しています。熱活性型薬剤輸送システムと熱エネルギーを集約化させた新規の腫瘍標的薬を開発しています。

当レポートでは、Celsion Corporationにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Celsion Corporationの基本情報

  • Celsion Corporationの概要
  • 主要情報
  • 企業情報

Celsion Corporation:R&Dの概要

  • 主な治療範囲

Celsion Corporation:パイプラインの分析

  • 開発段階別のパイプライン製品
  • 単剤製品

Celsion Corporation:パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
    • 第?相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Celsion Corporation:薬剤プロファイル

  • doxorubicin liposomal
  • EGEN-001
  • carboplatin liposomal
  • docetaxel liposomal
  • EGEN-002
  • Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension

Celsion Corporation:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Celsion Corporation:最近のパイプライン情報

Celsion Corporation:開発休止中のプロジェクト

Celsion Corporation:開発が中止されたパイプライン製品

Celsion Corporation:企業理念

Celsion Corporation:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07107CDB

Summary

Global Markets Direct's, 'Celsion Corporation - Product Pipeline Review - 2015', provides an overview of the Celsion Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celsion Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Celsion Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Celsion Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Celsion Corporation's pipeline products

Reasons to buy

  • Evaluate Celsion Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Celsion Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Celsion Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Celsion Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celsion Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Celsion Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Celsion Corporation Snapshot
    • Celsion Corporation Overview
    • Key Information
    • Key Facts
  • Celsion Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Celsion Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Celsion Corporation - Pipeline Products Glance
    • Celsion Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Celsion Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Celsion Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Celsion Corporation - Drug Profiles
    • doxorubicin liposomal
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EGEN-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carboplatin liposomal
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel liposomal
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EGEN-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Celsion Corporation - Pipeline Analysis
    • Celsion Corporation - Pipeline Products by Target
    • Celsion Corporation - Pipeline Products by Route of Administration
    • Celsion Corporation - Pipeline Products by Molecule Type
    • Celsion Corporation - Pipeline Products by Mechanism of Action
  • Celsion Corporation - Recent Pipeline Updates
  • Celsion Corporation - Dormant Projects
  • Celsion Corporation - Company Statement
  • Celsion Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Celsion Corporation, Key Information
  • Celsion Corporation, Key Facts
  • Celsion Corporation - Pipeline by Indication, 2015
  • Celsion Corporation - Pipeline by Stage of Development, 2015
  • Celsion Corporation - Monotherapy Products in Pipeline, 2015
  • Celsion Corporation - Phase III, 2015
  • Celsion Corporation - Phase II, 2015
  • Celsion Corporation - Phase I, 2015
  • Celsion Corporation - Preclinical, 2015
  • Celsion Corporation - Pipeline by Target, 2015
  • Celsion Corporation - Pipeline by Route of Administration, 2015
  • Celsion Corporation - Pipeline by Molecule Type, 2015
  • Celsion Corporation - Pipeline Products by Mechanism of Action, 2015
  • Celsion Corporation - Recent Pipeline Updates, 2015
  • Celsion Corporation - Dormant Developmental Projects,2015
  • Celsion Corporation, Subsidiaries

List of Figures

  • Celsion Corporation - Pipeline by Top 10 Indication, 2015
  • Celsion Corporation - Pipeline by Stage of Development, 2015
  • Celsion Corporation - Monotherapy Products in Pipeline, 2015
  • Celsion Corporation - Pipeline by Top 10 Target, 2015
  • Celsion Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Celsion Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Celsion Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top